Efficacy of lapatinib combined with microwave hyperthermia in the treatment of HER2-positive advanced breast cancer
10.3969/j.issn.1673-9701.2024.16.002
- VernacularTitle:拉帕替尼联合微波热疗治疗HER2阳性晚期乳腺癌的疗效
- Author:
Yuefeng ZHU
1
;
Jianwen SONG
;
Yanyan DAI
Author Information
1. 湖州市中心医院乳腺外科,浙江湖州 313000
- Keywords:
Lapatinib;
Microwave hyperthermia;
Human epidermal growth factor receptor 2;
Advanced breast cancer;
Vimentin;
Survival time
- From:
China Modern Doctor
2024;62(16):4-8
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of lapatinib combined with microwave hyperthermia in the treatment of human epidermal growth factor receptor 2(HER2)positive advanced breast cancer.Methods A total of 134 patients with HER2-positive advanced breast cancer treated in Huzhou Central Hospital from January 2019 to January 2020 were selected and divided into control group and observation group according to the lottery method,with 67 cases in each group.Both groups were treated with lapatinib,and the patients of observation group was treated with microwave hyperthermia on this basis.Tumor markers[carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),tissue peptide antigen(TPA)],the number of circulating tumor cells(CTC),vimentin expression and quality of life were compared between two groups before and after treatment.The clinical efficacy and survival status of two groups were analyzed.Results After treatment,CA153,CEA,TPA,the number of CTC and vimentin expression in two groups were significantly lower than before treatment,and the quality of life score was significantly higher than before treatment(P<0.05).CA153,CEA,TPA,the number of CTC and vimentin expression in observation group were significantly lower than those in control group,and the quality of life score was significantly higher than that in control group(P<0.05).The total effective rate of observation group was significantly higher than that of control group(χ2=5.350,P=0.021).There was no significant difference in adverse reactions between two groups(P>0.05).After 24 months of follow-up,the overall survival and progression-free survival of observation group were significantly longer than those of control group,and the 24-month cumulative survival rate was higher than that of control group(P<0.05).Conclusion Lapatinib combined with microwave hyperthermia has a good effect in the treatment of HER2-positive advanced breast cancer,which can change vimentin expression,inhibit disease progression and prolong the survival of patients.
